Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
191 hedge funds and large institutions have $2.1B invested in Intercept Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 61 increasing their positions, 55 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
57% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 28
11% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 55
9% more funds holding
Funds holding: 175 → 191 (+16)
14% less capital invested
Capital invested by funds: $2.42B → $2.1B (-$328M)
29% less call options, than puts
Call options by funds: $159M | Put options by funds: $225M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$62.2M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$29.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$29.4M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$24.8M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$30.2M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$21.1M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$19.7M |
| 4 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$16.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.8M |
ICPT Hedge Fund Activity: Q4 2018 in Review
191 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2018, worth a combined $2.1B — down 14% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ICPT positions and 28 closed out — a net gain of 16 holders — while 61 added to existing stakes and 55 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $62.2M. The largest seller was Highfields Capital Management, exiting entirely with an estimated $30.2M sold.
- 191 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2018, up from 175 in Q3 2018.
- Funds reported $2.1B of Intercept Pharmaceuticals, Inc. stock for Q4 2018, down 14% quarter-over-quarter.
- 44 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2018 and 28 closed out, a net change of +16 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2018 was Boxer Capital, an estimated $62.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2018 was Highfields Capital Management, an estimated $30.2M sold.
Based on aggregated 13F filings for Q4 2018.